A Randomized Phase 2 Trial of a Preparative Regimen of Bortezomib, High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid

Cancer - United States
doi 10.1002/cncr.26517
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

BU, Melphalan and Thiotepa as a Preparative Regimen for Auto-Transplantation in Hodgkin’s Disease

Bone Marrow Transplantation
TransplantationHematology
2011English

Rapid VAC High Dose Melphalan Regimen, a Novel Chemotherapy Approach in Childhood Soft Tissue Sarcomas

British Journal of Cancer
Cancer ResearchOncology
1991English

Docosahexaenoic Acid Enhances Arsenic Trioxide-Mediated Apoptosis in Arsenic Trioxide-Resistant HL-60 Cells

Blood
BiochemistryImmunologyCell BiologyHematology
2003English

The Preparation of High-Purity Arsenic. IV. The Reduction of Arsenic Trichloride and Arsenic Trioxide

The Journal of the Society of Chemical Industry, Japan
1963English

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

Cancer
Cancer ResearchOncology
2018English

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2015English

High-Dose BCNU/Melphalan Conditioning Regimen Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2017English

A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Dose-Response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy